Echocardiographic data demonstrated that FSTL1 administration significantly increased LVEF and LVFS and decreased LVIDd, LVIDs, heart weight and heart weight to body weight ratio compared to those in T2DM-MI group. The gene discussed is FSTL1; the disease is type 2 diabetes mellitus.